Search results
Results from the WOW.Com Content Network
Citi group has initiated coverage on GSK plc's (NYSE: GSK) consumer healthcare spin-off Haleon Plc (NYSE: HLN) with a Buy rating and a price target of 360p. "We see the company as the best vehicle ...
GSK sold around 385 million shares at 324 pence apiece, amounting to a 4.2% stake in Haleon. The company was formed in a merger of GSK and Pfizer's consumer healthcare businesses in 2019. The sale ...
GSK earlier this year sold 240 million shares in Haleon to raise about 804 million pounds ($1 billion), and lowered its stake from 12.9% it initially retained in the business.
Haleon was established on 18 July 2022 as a corporate spin-off from GSK. [6] Sir Dave Lewis is chairman, with Brian McNamara as CEO. [7] Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange. Annual sales amounted to around £10 billion across 120 markets in ...
Shares in Haleon, which was created by the merger of GSK and Pfizer's consumer healthcare businesses in 2019 and spun off from the British drugmaker in 2022, fell 1.2% to 388 pence in morning ...
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm.
The latest offload will mark the fourth set of disposal GSK has had in the Sensodyne toothpaste maker in a year. GSK, which initially retained a near 13% stake in Haleon, had over the course of a ...
British drugmaker GSK spun off its consumer health business on Monday in the biggest listing in Europe for more than a decade, but the unit's market value of 30.5 billion pounds fell well short of ...